Loading...
XNAS
NUWE
Market cap2mUSD
Dec 05, Last price  
2.43USD
1D
-7.60%
1Q
-50.20%
IPO
-100.00%
Name

Nuwellis Inc

Chart & Performance

D1W1MN
XNAS:NUWE chart
P/E
—
P/S
0.25
EPS
—
Div Yield, %
—
Shrs. gr., 5y
339.33%
Rev. gr., 5y
9.66%
Revenues
9m
-1.40%
381,7611,253,1212,731,740422,040108,302400,0250059,000295,00059,0001,289,0003,553,0004,998,0005,511,0007,441,0007,921,0008,543,0008,864,0008,740,000
Net income
-11m
L-47.43%
000000-16,196,000-14,065,000-21,758,000-25,587,000-26,583,000-15,792,000-13,382,000-17,032,000-18,114,000-15,836,000-19,578,000-14,525,000-20,209,000-10,624,000
CFO
-10m
L-46.53%
000000-13,089,000-13,083,000-17,362,000-22,644,000-22,989,000-16,292,000-11,920,000-14,560,000-16,367,000-16,572,000-17,880,000-15,149,000-17,937,000-9,591,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
URL
https://www.nuwellis.com/
IPO date
Feb 16, 2012
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT